Cite
HARVARD Citation
Fuse, M. et al. (2019). Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development. Neuro-oncology. 21 (4), pp. 486-497. [Online].